No registrations found.
ID
Source
Brief title
Health condition
Long-term memory
Sponsors and support
Intervention
Outcome measures
Primary outcome
To establish the effects of CILTEP on cognition, especially memory. The main cognitive tests that will be used are the verbal learning task (VLT), in which participants need to memorize words that are presented on a screen, and the spatial pattern separation test, using photographs to assess episodic memory.
Secondary outcome
Performance in several other cognitive tests will be our secondary objective. We will examine the effects of CILTEP on working memory performance using an n-back task, on information processing speed using the digit symbol substitution test (DSST), on motor speed using a simple and choice reaction time task (SRT and CRT, respectively), on attention and concept shifting using the trail making test, and on response inhibition and focused attention using the Stroop. A sensory gating paradigm is included to examine the effect of our treatment on specific ERP components related to basic auditory processing.
Background summary
N/A
Study objective
- CILTEP can improve cognition in healthy volunteers, specifically memory
- The effects of CILTEP will be discernable in the ERP components measured: the P50, P300, N400, and P600 amplitudes are expected to be enlarged by CILTEP
Study design
N/A
Intervention
Volunteers will be tested on 2 separate days and will be administered either CILTEP or a placebo. Before inclusion, they will undergo a memory and a medical screening The order of treatment will be randomized.
Dept. of Neuropsychology and Psychopharmacology
PO Box 616
Anke Sambeth
Maastricht 6200 MD
The Netherlands
0031-(0)43-3881757
anke.sambeth@psychology.unimaas.nl
Dept. of Neuropsychology and Psychopharmacology
PO Box 616
Anke Sambeth
Maastricht 6200 MD
The Netherlands
0031-(0)43-3881757
anke.sambeth@psychology.unimaas.nl
Inclusion criteria
1. Male or female;
2. 30 to 40 or 60 to 75 years of age;
3. healthy (i.e. absence of all exclusion criteria);
4. body mass index between 18.5 and 30;
5. Verbal Learning Test screening score within the -1 and +1 standard deviation;
6. willingness to sign an informed consent.
Exclusion criteria
1. history of cardiac, hepatic, renal, pulmonary, neurological, gastrointestinal, haematological, or psychiatric ilness or a first-degree relative with a psychiatric disorder or a history with a psychiatric disorder;
2. excessive drinking (> 20 glasses of alcohol containing beverages a week);
3. pregnancy or lactation;
4. use of use of psychoactive medication or centrally acting beta blockers;
5. use of recreational drugs from 2 weeks before the experiment until the end of the study;
6. systolic blood pressure above 160 mmHg;
7. phenylketonuria;
8. any sensory or motor deficits which could reasonably be expected to affect test performance;
9. use of steroids or Sudafed (pseudoephedrine)
Design
Recruitment
IPD sharing statement
Followed up by the following (possibly more current) registration
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL6001 |
| NTR-old | NTR6400 |
| CCMO | NL60999.068.17 |
| OMON | NL-OMON47611 |